This review explores the role of brain-derived neurotrophic factor (BDNF) in the regulation of nociception and pain. BDNF, a neurotrophin essential for neuronal survival and plasticity, has been shown to modulate synaptic transmission and is involved in both physiological and pathological pain conditions. The article discusses the molecular mechanisms underlying BDNF's involvement in pain processing and highlights potential therapeutic applications of BDNF and its mimetics in managing pain. It also reviews recent advancements and challenges in translating BDNF-related research into clinical practice. BDNF is a member of the neurotrophin family, including nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5). It is primarily synthesized as a precursor protein called proBDNF, which is proteolytically cleaved to generate mature BDNF. The mature BDNF protein consists of 247 amino acids and forms a homodimer. It activates the trkB receptor, while proBDNF activates the p75NTR receptor. BDNF induces long-term potentiation (LTP), whereas proBDNF sustains long-term depression (LTD) at synapses. BDNF is involved in the induction of synaptic plasticity, leading to increased responsiveness of peripheral nociceptors to nociceptive stimuli. It plays a role in both peripheral and central sensitization. Inflammatory processes are often accompanied by increased BDNF release, which can have both neuroprotective and detrimental effects. Lesions of the peripheral nerves leading to neuropathic pain may be accompanied by upregulation of BDNF and activation of the BDNF/trkB signaling cascade. BDNF is expressed in various neurons of the somatic and visceral pathways, including primary sensory neurons (PSNs), second-order neurons (SSNs), and higher-order neurons. It is also found in glial cells, such as microglia. BDNF modulates synaptic plasticity in the spinal cord and the spinal nucleus of the trigeminal nerve (SNTN), where nociceptive signals are first processed. BDNF enhances glutamate release and modifies the function of AMPARs and NMDARs, resulting in amplified nociceptive signals through LTP, which is crucial for central sensitization. Ex vivo studies have shown that BDNF enhances the release of sensory neurotransmitters in the substantia gelatinosa and induces electrical patterns similar to those observed in chronic constriction injury (CCI) models. In vivo studies have demonstrated that BDNF is a pro-nociceptive modulator in inflammatory pain, enhancing glutamatergic transmission in the spinal dorsal horn through NMDAR plasticity. BDNF also increases the amplitude and frequency of spontaneous excitatory postsynaptic currents (sEPSC) and miniature excitatory postsynaptic currents (This review explores the role of brain-derived neurotrophic factor (BDNF) in the regulation of nociception and pain. BDNF, a neurotrophin essential for neuronal survival and plasticity, has been shown to modulate synaptic transmission and is involved in both physiological and pathological pain conditions. The article discusses the molecular mechanisms underlying BDNF's involvement in pain processing and highlights potential therapeutic applications of BDNF and its mimetics in managing pain. It also reviews recent advancements and challenges in translating BDNF-related research into clinical practice. BDNF is a member of the neurotrophin family, including nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5). It is primarily synthesized as a precursor protein called proBDNF, which is proteolytically cleaved to generate mature BDNF. The mature BDNF protein consists of 247 amino acids and forms a homodimer. It activates the trkB receptor, while proBDNF activates the p75NTR receptor. BDNF induces long-term potentiation (LTP), whereas proBDNF sustains long-term depression (LTD) at synapses. BDNF is involved in the induction of synaptic plasticity, leading to increased responsiveness of peripheral nociceptors to nociceptive stimuli. It plays a role in both peripheral and central sensitization. Inflammatory processes are often accompanied by increased BDNF release, which can have both neuroprotective and detrimental effects. Lesions of the peripheral nerves leading to neuropathic pain may be accompanied by upregulation of BDNF and activation of the BDNF/trkB signaling cascade. BDNF is expressed in various neurons of the somatic and visceral pathways, including primary sensory neurons (PSNs), second-order neurons (SSNs), and higher-order neurons. It is also found in glial cells, such as microglia. BDNF modulates synaptic plasticity in the spinal cord and the spinal nucleus of the trigeminal nerve (SNTN), where nociceptive signals are first processed. BDNF enhances glutamate release and modifies the function of AMPARs and NMDARs, resulting in amplified nociceptive signals through LTP, which is crucial for central sensitization. Ex vivo studies have shown that BDNF enhances the release of sensory neurotransmitters in the substantia gelatinosa and induces electrical patterns similar to those observed in chronic constriction injury (CCI) models. In vivo studies have demonstrated that BDNF is a pro-nociceptive modulator in inflammatory pain, enhancing glutamatergic transmission in the spinal dorsal horn through NMDAR plasticity. BDNF also increases the amplitude and frequency of spontaneous excitatory postsynaptic currents (sEPSC) and miniature excitatory postsynaptic currents (